81 related articles for article (PubMed ID: 17627421)
21. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
22. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
23. 4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: evaluation using a fillable kidney phantom imaged by 90Y PET.
Walrand S; Jamar F; van Elmbt L; Lhommel R; Bekonde EB; Pauwels S
J Nucl Med; 2010 Dec; 51(12):1969-73. PubMed ID: 21078802
[TBL] [Abstract][Full Text] [Related]
24. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
[TBL] [Abstract][Full Text] [Related]
25. Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC.
Ferrari M; Cremonesi M; Bartolomei M; Bodei L; Chinol M; Fiorenza M; Tosi G; Paganelli G
J Nucl Med; 2006 Jan; 47(1):105-12. PubMed ID: 16391194
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.
Bushnell D; O'Dorisio T; Menda Y; Carlisle T; Zehr P; Connolly M; Karwal M; Miller S; Parker S; Bouterfa H
J Nucl Med; 2003 Oct; 44(10):1556-60. PubMed ID: 14530466
[TBL] [Abstract][Full Text] [Related]
27. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
Cremonesi M; Ferrari M; Chinol M; Bartolomei M; Stabin MG; Sacco E; Fiorenza M; Tosi G; Paganelli G
Q J Nucl Med; 2000 Dec; 44(4):325-32. PubMed ID: 11302260
[TBL] [Abstract][Full Text] [Related]
28. Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
Cybulla M; Weiner SM; Otte A
Med Sci Monit; 2002 Apr; 8(4):LE7. PubMed ID: 11951054
[No Abstract] [Full Text] [Related]
29. Significant impact of transient deterioration of renal function on dosimetry in PRRT.
Van Binnebeek S; Baete K; Terwinghe C; Vanbilloen B; Haustermans K; Mortelmans L; Borbath I; Van Cutsem E; Verslype C; Mottaghy FM; Verbruggen A; Deroose CM
Ann Nucl Med; 2013 Jan; 27(1):74-7. PubMed ID: 22961123
[TBL] [Abstract][Full Text] [Related]
30. New advances in peptide receptor radionuclide therapy.
de Jong M; Krenning E
J Nucl Med; 2002 May; 43(5):617-20. PubMed ID: 11994523
[No Abstract] [Full Text] [Related]
31. Yttrium-based therapy for neuroendocrine tumors.
Bodei L; Cremonesi M; Paganelli G
PET Clin; 2014 Jan; 9(1):71-82. PubMed ID: 25029936
[TBL] [Abstract][Full Text] [Related]
32. Particle filter de-noising of voxel-specific time-activity-curves in personalized
Götz TI; Lang EW; Schmidkonz C; Maier A; Kuwert T; Ritt P
Z Med Phys; 2020 May; 30(2):116-134. PubMed ID: 31859029
[TBL] [Abstract][Full Text] [Related]
33. [(111)In]DOTATOC as a dosimetric substitute for kidney dosimetry during [(90)Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.
Stahl A; Schachoff S; Beer A; Winter A; Wester HJ; Scheidhauer K; Schwaiger M; Wolf I
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1328-36. PubMed ID: 16645839
[TBL] [Abstract][Full Text] [Related]
34. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.
Moll S; Nickeleit V; Mueller-Brand J; Brunner FP; Maecke HR; Mihatsch MJ
Am J Kidney Dis; 2001 Apr; 37(4):847-51. PubMed ID: 11273886
[TBL] [Abstract][Full Text] [Related]
35. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
[TBL] [Abstract][Full Text] [Related]
37. Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer.
Beauregard JM
Cancer Imaging; 2022 Dec; 22(1):67. PubMed ID: 36494731
[TBL] [Abstract][Full Text] [Related]
38. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy.
Giovacchini G; Nicolas G; Freidank H; Mindt TL; Forrer F
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1675-82. PubMed ID: 21553088
[TBL] [Abstract][Full Text] [Related]
39. One single-time-point kidney uptake from OctreoScan correlates with number of desintegrations measured over 72 hours and calculated for the 6.7 hours half-life nuclide (177)Lu.
Miederer M; Reber H; Helisch A; Fottner C; Weber M; Schreckenberger M
Clin Nucl Med; 2012 Oct; 37(10):e245-8. PubMed ID: 22899194
[TBL] [Abstract][Full Text] [Related]
40. Production and quality control of [(90)Y]DOTATOC for treatment of metastatic neuroendocrine tumors: results of 85 syntheses.
Biasiotto G; Bertagna F; Zanella I; Biasiotto U; Savelli G; Caimi L; Bettinsoli G; Giubbini R; Chinol M
Nucl Med Commun; 2013 Mar; 34(3):265-70. PubMed ID: 23276826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
